BPC-157 and TB-500 (thymosin beta-4) are the two peptides Australian patients ask about most often for soft-tissue recovery. Neither is ARTG-approved; both can be lawfully prescribed by an AHPRA-registered Australian doctor under TGA SAS-B when clinically appropriate. They're often described as interchangeable. They're not — they work on different mechanisms and suit different injury patterns.
BPC-157 mechanism: a synthetic 15-amino-acid sequence derived from a protective protein found in human gastric juice. The body of preclinical work points to angiogenesis (new blood vessel formation) and modulation of growth factors like VEGF and FGF as core mechanisms. Effect is most studied at the site of administration — which is why BPC-157 is often injected near the injured tendon or ligament rather than purely systemically.
TB-500 mechanism: a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid peptide involved in cell migration and actin regulation. TB-500 is more systemic — it tends to circulate and act on cells throughout the body, with particular research interest in cardiac, dermal, and muscular tissue repair.
Best-fit indications, as Australian prescribers tend to frame them: - BPC-157: localised tendon and ligament injuries (Achilles, patellar, rotator cuff), gut-lining issues adjunctive to standard care, post-surgical soft-tissue recovery. - TB-500: more diffuse soft-tissue recovery, muscle strain across multiple groups, complex injuries with vascular components. - Many prescribers run them together (the "BPC + TB" stack) for complex or stalled recoveries.
Evidence base: Both peptides sit in the same regulatory bucket — not on the ARTG, modest published human evidence, larger preclinical literature. Long-term human safety data is limited for both. Neither is a first-line therapy for any condition. They're reviewed case-by-case by your Australian doctor against what conventional rehab has been tried.
Free guide: Legal Peptides in Australia (2026)
What's legal under TGA SAS-B, which peptides Australian doctors actually prescribe, real costs, and the questions to ask at your consult.
No spam. Unsubscribe any time. See our privacy policy.
Administration: BPC-157 is most often subcutaneous, sometimes injected close to the affected site. TB-500 is typically subcutaneous or intramuscular, less site-specific, with loading and maintenance phases (e.g. higher dose weekly for 4–6 weeks, then a maintenance dose). Both come as compounded sterile vials from a TGA-licensed Australian compounding pharmacy.
Cost in Australia (2026): BPC-157 runs roughly AUD $180–$320/month compounded. TB-500 sits a little higher, roughly AUD $250–$400/month, due to the larger molecule and synthesis cost. Running both together is typically $400–$650/month combined. Initial telehealth consult is $99.
Cautions: Neither is suitable in pregnancy, breastfeeding, or with active malignancy. The angiogenic mechanism is also why prescribers are cautious in patients with a personal cancer history — new blood vessel formation is exactly the wrong signal to amplify in that setting. Your prescriber will go through your medical history before recommending either.
So which one? For a localised tendon issue that won't budge, BPC-157 first. For a diffuse, multi-site recovery problem or a complex injury, TB-500 (or the stack) is often where prescribers go. The decision is your doctor's, not a blog post's. If you're considering either, the right next step is a telehealth consult where an Australian doctor can review your imaging, history, and what conventional rehab has been tried.
Avoid: any "research peptide" BPC-157 or TB-500 sold online without an Australian prescription. The vials are not subject to identity, sterility, or potency testing, and importing them is an offence under the Customs Act regardless of how the offshore vendor labels them.